Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Faricimab vs Aflibercept in Macular Edema Secondary to RVO
CTR20210149Phase 3Completed
- Sponsor
- Roche
- Start
- Feb 2021
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of faricimab in central retinal vein occlusion with macular edema, macular edema, sponsored by Roche. Started Feb 2021; status: completed.
02
Drugs
faricimab
03
Conditions
central retinal vein occlusion with macular edemamacular edema
Beyond the preview
Go deeper on CTR20210149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210149.